MiR-34a modulates ErbB2 in breast cancer.
Breast cancer is the second highest cause of carcinoma-related death caused by distant metastasis in women. Estrogen receptor (ER), human epidermal growth factor receptor 2, (HER2) and progesterone receptor (PR) are three classified makers of breast cancer, which are defined as ER+, HER2+, and the most serious ER-PR-HER2- (triple-negative). It is well known that ErbB2 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 2) plays an important part in breast cancer. However, the molecular mechanisms underlying ErbB2 action needs to be well studied. In this report, we discovered that the decreased expression levels of miR-34a were inversely correlated with the increased ErbB2 levels in breast cancer. A luciferase reporter assay was done to understand the potential correlation between ErbB2 and miR-34a. Over-expression of miR-34a reduces ErbB2 expression and suppresses breast cancer cell invasion and growth in vitro. What's more, reduced expression of ErbB2 inhibits breast Cancer cell proliferation and re-expression of ErbB2 reversed miR-34a-dependent tumor suppression. Meanwhile, miR-34a levels were correlated inversely with breast cancer malignancy. Our study demonstrates that miR-34a, like ErbB2, might be a diagnostic target in breast cancer.
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.
Yilin
Y
Wang
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.
Xiaolong
X
Zhang
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.
Zou
Z
Chao
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.|Faculty of Medicine, The Chinese University of Hong Kong, Tai Po Rd, Hong Kong.
Hsiang-Fu
HF
Kung
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.|Brain Tumor Center, Neurosurgery Division, Faculty of Medicine, PWH, The Chinese University of Hong Kong, Tai Po Rd, Hong Kong.
Marie C
MC
Lin
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.|CAS-MPG Partner Institute and Key Lab for Computational Biology, SIBS, CAS, Yue Yang Road, Shanghai, 200062, China.
Andreas
A
Dress
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.|Randall Division of Cell and Molecular Biophysics, New Hunt's House, King's College London, Guy's Campus, WC2R 2LS, London, UK.
Fiona
F
Wardle
State Key lab of Reproductive Medicine, and Department of Pathology, Cancer Center, Nanjing Medical University, Hanzhong Rd, Nanjing, 210029, China.|Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Walnut St, Philadelphia, 19107, USA.
Bing-Hua
BH
Jiang
Institute of Molecular and Chemical Biology, East China Normal University, North Zhongshan Road, Shanghai, 200062, China.
Lihui
L
Lai
D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*
D035683:MicroRNAs; D018719:Erb-b2 Receptor Tyrosine Kinases; C522425:MIRN34 microRNA, human; C508053:ERBB2 protein, human
ErbB2; MiR-34a; breast cancer